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Atrial fibrillation or patent foramen ovale: where is the cause 
of recurrent ischemic strokes?
Migotanie przedsionków czy przetrwały otwór owalny — gdzie leży przyczyna  
nawracających udarów niedokrwiennych mózgu?
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Abstract
Ischemic stroke is one of the major causes of death and disability in high-developed countries. Closure of patent 
foramen ovale (PFO) is recommended if other causes of ischemic stroke, such as atrial fibrillation (AF), are excluded, 
especially in young patients. We present a case report of a 75-years-old female patient with five ischemic strokes in 
her medical history and newly diagnosed PFO. Atrial fibrillation was detected 25 years after first ischemic event. Imple-
mentation of anticoagulation therapy has prevented new ischemic strokes in this patient. According to emerging meta-
-analyses such treatment is sufficient not only in AF, but also in PFO related ischemic strokes. The patient had other risk 
factors for paradoxical embolism such as varices, post-thrombotic syndrome of lower limbs and the Eustachian valve, so 
it is unclear whether AF has been the major cause of all ischemic strokes in present case. Significant bleeding from limb 
varices during anticoagulation treatment occurred and required urgent surgical intervention. Because of the high risk of 
recurrent hemorrhages (HAS-BLED Score — 4 points), the patient was considered for two percutaneous procedures: oc-
clusion of the left atrial appendage and consecutively the second one — PFO closure as additional prevention of stroke.
This is an illustrative case that opens discussion on necessity and timing of cardiac interventions once possible cardiac 
sources of ischemic strokes are found and new facts arise.
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Introduction
Ischemic stroke is one of the major causes of death and 
disability in high-developed countries [1]. Atrial fibrillation 
(AF) is responsible for around one third of all ischemic 
strokes [2]. The role of patent foramen ovale (PFO) has 
been widely discussed especially in younger individuals 
and closure of PFO is recommended if other causes of 
ischemic stroke were excluded [3].
Case report
A 75-years-old female patient with five ischemic strokes in 
her medical history (1986–2012) and multiple other comor-
bidities (heart failure with reduced left ventricle ejection 
fraction, coronary artery disease treated with coronary-
-artery by-pass grafting in 2007, paroxysmal AF (PAF), sy-
stemic hypertension, diabetes mellitus type 2, lower limbs’ 
varices disqualified to surgical treatment, post-thrombotic 
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Anticoagulation treatment is not inferior to PFO closure 
as comes to prevention of recurrence of ischemic strokes 
and both these options are superior to the antiplatelet 
therapy [6–8]. In European position paper on the manage-
ment of patients with PFO expert recommend to carefully 
select patients for percutaneous closure of PFO in case of 
cryptogenic ischemic stroke [3]. It is advised especially in 
younger patients (18–65yrs) in the case of lack of other 
possible causes of ischemic stroke. Individual approach for 
patients over 65yrs is recommended. It is unclear whether 
AF has been the major cause of ischemic stroke in present 
case; especially, considering that it was detected 25 years 
after first ischemic event. The patient was evaluated using 
RoPE score, which did not give an exact conclusion on the 
role of PFO. Active bleeding during anticoagulation gene-
rated a new problem. LAA occlusion may be considered 
as an alternative to anticoagulation therapy in patients 
with contraindications to antithrombotic treatment [5]. 
Consensus Document for percutaneous occlusion of the 
LAA in patients with non-valvular AF also points to other 
indications for LAA closure than bleeding, such as elder-
liness or risk of frequent falls [9]. This is an additional 
argument in favor of LAA occlusion in our patient. The 
question about PFO closure is still open; however, it seems 
reasonable after LAA occlusion. This is an illustrative case 
that opens discussion on necessity and timing of cardiac 
interventions once possible cardiac sources of ischemic 
strokes are found and new facts arise. Probably no definite 
answers can be found yet if there is still time to wait with 
possible interventions in this kind of patient and continue 
pharmacological treatment. Should those procedures be 
performed simultaneously? If this is feasible, probably yes. 
This kind of attempt reduces complication rate linked to 




syndrome) was admitted because of non-ST elevation my-
ocardial infarction in 2019. The coronary arteriography sho-
wed patent grafts and probably chronic occlusion of the left 
anterior descending artery (LAD) distal to anastomosis. An 
attempt to open chronically occluded LAD was unsuccessful 
and decision on conservative treatment was made by the 
Heart Team. The echocardiographic examination confirmed 
reduced left ventricular ejection fraction (LVEF 30%) and for 
the first time revealed spontaneous left-to-right shunt in in-
teratrial septum (IAS) and presence of the Eustachian valve. 
Transesophageal echocardiography visualized patent PFO 
with right-to left shunt induced by Valsalva maneuver. This 
finding made paradoxical embolism another possible cause 
of recurrent ischemic strokes next to PAF. This arrhythmia 
was recorded for the first time in 2012 just after the last 
stroke (CHA2DS2-VASc score — 9 points). Anticoagulation 
therapy was started immediately after diagnosis. The pa-
tient had other risk factors for paradoxical embolism such 
as varices, post-thrombotic syndrome of lower limbs and 
the Eustachian valve [3]. Ultrasonography of the carotid 
arteries was normal.
We stratified the patient’s risk using the Risk of Para-
doxical Embolism (RoPE) score dedicated to differentiate 
stroke-related vs incidental PFO [4]. See Table 1.
At discharge, rivaroxaban (20 mg/d.) plus clopidogrel 
(75 mg/d.) were administered. One month after discharge 
a significant bleeding from limb varices occurred that requi-
red urgent surgical intervention. Because of the high risk of 
recurrent hemorrhages (HAS-BLED Score — 4 points), the 
patient was considered for two percutaneous procedures: 
occlusion of the left atrial appendage (LAA) and consecu-
tively PFO closure as additional prevention of stroke [3, 5].
Discussion
Implementation of anticoagulation therapy in 2012 has 
prevented new ischemic strokes in our patient. According 
to emerging meta-analyses such treatment is sufficient not 
only in AF, but also in PFO related ischemic strokes [6–8]. 
Table 1. Risk of Paradoxical Embolism (RoPE) Score results over the years
1986 2003 2005 2009 2012
History of hypertension (No — 1 point; Yes — 0 points) No Yes Yes Yes Yes
History of diabetes (No — 1 point; Yes — 0 points) No No No Yes Yes
History of stroke/TIA (No — 1 point; Yes — 0 points) No Yes Yes Yes Yes
Smoker (No — 1 point; Yes — 0 points) No No No No No
Cortical infarct on imaging (Yes — 1 point; No — 0 points) Yes Yes Yes Yes Yes
Age (18–29 yrs — 5 points; 30–39 yrs — 4 points; 40–49 yrs — 3 po-
ints; 50–59 yrs — 2 points; 60–69 yrs — 1 point; ≥ 70 yrs — 0 points)
43 yrs 60 yrs 62 yrs 66 yrs 69 yrs
8 points 4 points 4 points 3 points 3 points
Chance of PFO-related stroke 84% 38% 38% 0% 0%
TIA — transient ischemic disease; PFO — patent foramen ovale
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Streszczenie
Udar niedokrwienny mózgu jest istotną przyczyną niepełnosprawności oraz zgonów w krajach wysokorozwiniętych. 
Zamknięcie drożnego otworu owalnego (PFO) jest zalecane, jeśli wykluczy się inne, częstsze przyczyny udaru niedo-
krwiennego, takie jak migotanie przedsionków (AF), co szczególnie dotyczy młodszych pacjentów. Zaprezentowano 
przypadek 75-letniej chorej z wywiadem pięciu udarów niedokrwiennych mózgu w okresie 26 lat oraz nowo wykrytym 
PFO. Migotanie przedsionków zdiagnozowano 25 lat po pierwszym udarze niedokrwiennym mózgu. Włączenie leczenia 
przeciwkrzepliwego zapobiegło wystąpieniu kolejnych udarów niedokrwiennych mózgu. Zgodnie z najnowszymi bada-
niami takie postępowanie jest skuteczne nie tylko w prewencji udarów związanych z AF, ale również z PFO. Chora była 
również obciążona wieloma innymi czynnikami ryzyka wystąpienia zatorów skrzyżowanych: żylakami kończyn dolnych, 
zespołem pozakrzepowym kończyn dolnych, zastawką Eustachiusza, dlatego też nie było jasne, czy to AF stanowiło 
główny czynnik wystąpienia wszystkich incydentów niedokrwiennych. Podczas leczenia przeciwkrzepliwego u pacjentki 
wystąpiło istotne krwawienie z żylaków kończyn dolnych, które wymagało pilnego leczenia chirurgicznego. Ze względu 
na wysokie ryzyko nawrotu krwawienia (HAS-BLED — 4 pkt.) u chorej rozważano wykonanie dwóch przezskórnych proce-
dur: zamknięcia uszka lewego przedsionka oraz następnie zamknięcia PFO jako dodatkowej prewencji przed kolejnymi 
udarami niedokrwiennymi ośrodkowego układu nerwowego.
Współwystępowanie AF i PFO otworzyło dyskusję dotyczącą do głównej przyczyny nawracających udarów niedokrwien-
nych mózgu. Zamknięcie uszka lewego przedsionka i PFO są alternatywnymi metodami zapobiegającymi udarom niedo-
krwiennym mózgu w przypadku przeciwwskazań do antykoagulacji.
Słowa kluczowe: antykoagulacja, migotanie przedsionków, udar niedokrwienny mózgu, przetrwały otwór owalny
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